AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
